SG11202004377XA - Smac mimetics used as iap inhibitors and use thereof - Google Patents

Smac mimetics used as iap inhibitors and use thereof

Info

Publication number
SG11202004377XA
SG11202004377XA SG11202004377XA SG11202004377XA SG11202004377XA SG 11202004377X A SG11202004377X A SG 11202004377XA SG 11202004377X A SG11202004377X A SG 11202004377XA SG 11202004377X A SG11202004377X A SG 11202004377XA SG 11202004377X A SG11202004377X A SG 11202004377XA
Authority
SG
Singapore
Prior art keywords
smac mimetics
iap inhibitors
mimetics used
iap
inhibitors
Prior art date
Application number
SG11202004377XA
Other languages
English (en)
Inventor
Yingchun Liu
Zhaobing Xu
Lihong Hu
Charles Z Ding
Xingxun Zhu
Guoping Hu
Jian Li
Shuhui Chen
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of SG11202004377XA publication Critical patent/SG11202004377XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202004377XA 2017-11-13 2018-11-13 Smac mimetics used as iap inhibitors and use thereof SG11202004377XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201711117079 2017-11-13
PCT/CN2018/115256 WO2019091492A1 (zh) 2017-11-13 2018-11-13 用作iap抑制剂的smac模拟物及其用途

Publications (1)

Publication Number Publication Date
SG11202004377XA true SG11202004377XA (en) 2020-06-29

Family

ID=66438734

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004377XA SG11202004377XA (en) 2017-11-13 2018-11-13 Smac mimetics used as iap inhibitors and use thereof

Country Status (16)

Country Link
US (1) US11358950B2 (de)
EP (1) EP3712162B1 (de)
JP (1) JP7257397B2 (de)
KR (1) KR102707188B1 (de)
CN (2) CN111247161B (de)
AU (1) AU2018364218B2 (de)
BR (1) BR112020009369A2 (de)
CA (1) CA3082437A1 (de)
DK (1) DK3712162T3 (de)
EA (1) EA202091169A1 (de)
ES (1) ES2927195T3 (de)
IL (1) IL274598B1 (de)
PL (1) PL3712162T3 (de)
SG (1) SG11202004377XA (de)
WO (1) WO2019091492A1 (de)
ZA (1) ZA202003178B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020233068A1 (en) * 2019-03-07 2021-09-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combination of IAP inhibitor and immune checkpoint inhibitor
US20220177453A1 (en) * 2019-05-10 2022-06-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystallization of smac mimic used as iap inhibitor and preparation method thereof
WO2024175554A1 (en) 2023-02-21 2024-08-29 Institut Curie Trail agonists for use in the treatment of cancer in patients having an activating alteration of fgfr3

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG152225A1 (en) 2004-04-07 2009-05-29 Novartis Ag Inhibitors of iap
US7244851B2 (en) 2004-07-02 2007-07-17 Genentech, Inc. Inhibitors of IAP
DK1836201T4 (da) * 2004-12-20 2013-11-11 Genentech Inc Pyrrolidininhibitorer af IAP.
AR064235A1 (es) 2006-07-24 2009-03-25 Tetralogic Pharmaceuticals Cor Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer
BRPI0719221A2 (pt) 2006-10-12 2014-03-18 Novartis Ag Derivados de pirrolidina como inibidores de iap
WO2008079735A1 (en) 2006-12-19 2008-07-03 Genentech, Inc. Imidazopyridine inhibitors of iap
CA2712604A1 (en) 2008-01-24 2009-07-30 Tetralogic Pharmaceutical Corporation Iap inhibitors
NO2755614T3 (de) 2012-01-03 2018-03-31
JP6513019B2 (ja) 2012-05-04 2019-05-15 ノバルティス アーゲー Iapインヒビター治療のためのバイオマーカー

Also Published As

Publication number Publication date
EP3712162A4 (de) 2021-08-04
CA3082437A1 (en) 2019-05-16
IL274598B1 (en) 2024-09-01
KR20200081456A (ko) 2020-07-07
CN111247161B (zh) 2021-12-31
AU2018364218A1 (en) 2020-06-04
IL274598A (en) 2020-06-30
AU2018364218B2 (en) 2023-03-02
EP3712162B1 (de) 2022-08-24
CN111247161A (zh) 2020-06-05
ES2927195T3 (es) 2022-11-03
PL3712162T3 (pl) 2022-11-14
CN114685602A (zh) 2022-07-01
ZA202003178B (en) 2022-10-26
EA202091169A1 (ru) 2020-08-06
JP7257397B2 (ja) 2023-04-13
EP3712162A1 (de) 2020-09-23
JP2021502397A (ja) 2021-01-28
WO2019091492A1 (zh) 2019-05-16
US20210371400A1 (en) 2021-12-02
US11358950B2 (en) 2022-06-14
BR112020009369A2 (pt) 2020-10-13
KR102707188B1 (ko) 2024-09-13
DK3712162T3 (da) 2022-09-19

Similar Documents

Publication Publication Date Title
IL271275A (en) Preparations containing coronas and their uses
IL270330B (en) Beta-lactamase inhibitors and their uses
HK1257642A1 (zh) 葫蘆脲組合物及其用途
RS64889B1 (sr) Inhibitori lsd1 i njihova medicinska upotreba
PL3621694T3 (pl) Inhibitory lrrc33 i ich zastosowanie
EP3271502A4 (de) Mehrlagige mikrofasern und verwendung davon
EP3234244A4 (de) Faserballrohbaumwolle füllung und artikel damit
EP3133153A4 (de) Neuartige bakteriophagen und zusammensetzung damit
ZA202003178B (en) Smac mimetics used as iap inhibitors and use thereof
HK1254620A1 (zh) 聯合抗菌組合物以及短療程抗菌方案
EP3133151A4 (de) Neuartige bakteriophagen und zusammensetzung damit
IL269836B (en) Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use
SG11202102182VA (en) Desiccant composition and use thereof
IL265531A (en) N 3 -cyclically substituted thienouraciles and use thereof
GB202004930D0 (en) Composition and uses thereof
GB2584009B (en) Aminoglycosides and uses thereof
HK1250915A1 (zh) 組合物和其用途
EP3135761A4 (de) Neuartige bakteriophagen und zusammensetzung damit
EP3343658A4 (de) Zusammensetzung und lichtemittierendes element damit
IL269843B (en) Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use
EP3389105A4 (de) Zusammensetzung und lichtemittierendes element damit
IL252660A0 (en) Compounds characterized by an inverse freezing property and their uses
GB201700981D0 (en) Composition and device
IL248576A0 (en) Anti-lice preparation and its uses
GB201621959D0 (en) Compositions and their use